Exercise at different intensities for metabolic dysfunction-associated steatotic liver disease
Compares high, moderate and low intensity exercise in adults with fatty liver disease.
Plain-language title generated from the registry record
Registry title: Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
Key facts
- Where
- Brussels and Louvain-la-Neuve, BelgiumSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06506513, who can take part
Where in Belgium
- Cliniques universitaires Saint-LucBrussels, BelgiumTaking people
- Centre d'investigation clinique en nutritionLouvain-la-Neuve, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Trial code
- NCT06506513
- Record updated
- 14 July 2026
- Original description
Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity. Conversely, MASLD histological remission though diet or metabolic surgeries is also linked to a decrease in muscle fat content. Therefore, skeletal muscle appears as a potential target to treat MASLD.Read full original descriptionShow less
Targeting Myosteatosis Though Physical Exercise to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity. Conversely, MASLD histological remission though diet or metabolic surgeries is also linked to a decrease in muscle fat content. Therefore, skeletal muscle appears as a potential target to treat MASLD.
Inclusion: confirmed MASLD at abdominal imaging; confirmed excessive muscle lipid content at imaging; stable weight.
Exclusion: severe comorbidities including active malignancies, neuromuscular degenerative diseases; contraindications to physical activity; excessive alcohol consumption.